Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
OXERVATE vs ACTISITE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
OXERVATE (becaplermin) is a recombinant human platelet-derived growth factor (rh PDGF-BB) that promotes wound healing by stimulating chemotaxis and mitogenesis of fibroblasts, smooth muscle cells, and other cells involved in tissue repair.
Tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-t RNA from binding to the A site.
Treatment of lower extremity diabetic neuropathic ulcers that extend into the subcutaneous tissue or beyond and have adequate blood supply,Off-label: Treatment of pressure ulcers, venous stasis ulcers
Treatment of periodontal disease (adjunct to scaling and root planing),Topical treatment of infected wounds and skin ulcers
1 drop in the affected eye(s) twice daily, approximately 6 hours apart.
Topical application of tetracycline hydrochloride 10 mg/g periodontal fiber. Inserted into periodontal pocket and left in place for 10 days.
Terminal elimination half-life of Cenegermin is approximately 12 hours following topical ocular administration, supporting once-daily dosing
Not applicable due to local degradation; systemic half-life is negligible as tetracycline hydrochloride is not absorbed.
Becaplermin is a protein that is expected to be degraded into small peptides and amino acids via general protein catabolism; specific hepatic metabolism is not a significant pathway.
Not significantly metabolized; primarily excreted unchanged in urine and feces.
Primarily renal elimination of the active metabolite (Cenegermin) as small peptides and amino acids; unchanged drug excretion is negligible
Primarily eliminated by phagocytic degradation at the application site; minimal systemic absorption, negligible renal or biliary excretion.
Cenegermin binding to plasma proteins is minimal (<10%) due to its small protein nature
Not applicable (no systemic absorption); if systemically present, tetracycline is 50-60% bound to plasma proteins.
Vd not determined for topical ocular route; systemic exposure is low, with Vd estimated less than 0.1 L/kg based on limited systemic absorption
Not applicable due to lack of systemic absorption; if systemic, tetracycline Vd is 1.3-1.6 L/kg.
Topical ocular: Systemic bioavailability is negligible (<1%) due to low corneal penetration and extensive proteolysis at the ocular surface
Negligible systemic bioavailability (<0.1%) when applied topically; not administered orally or intravenously for periodontal use.
No dose adjustment required for renal impairment.
Not systemically absorbed; no renal adjustment required.
No dose adjustment required for hepatic impairment.
Not systemically absorbed; no hepatic adjustment required.
Safety and efficacy in pediatric patients have not been established.
Safety and efficacy not established in pediatric patients.
No specific dose adjustment required; use same dosing as adults.
No specific dose adjustment; use standard adult dosing with caution for age-related comorbidities.
OXERVATE has been associated with an increased risk of mortality from secondary malignancies in patients who have had a malignant neoplasm. The drug should not be used in patients with active malignancy.
None
Increased risk of malignancy in patients with a history of malignancy; application to ulcers with malignant cells may promote tumor growth; use only on clean, non-infected ulcers; monitor for signs of infection; avoid application to wounds with exposed bone, tendon, or joint capsule.
Photosensitivity,Superinfection with resistant organisms,Use in renal impairment may require dose adjustment,Not recommended in children under 8 years due to permanent tooth discoloration
Known hypersensitivity to becaplermin or any product component; active neoplasm at the application site; patients with a history of malignancy (relative contraindication based on black box warning).
Hypersensitivity to tetracyclines,Severe renal impairment
None known; no significant food interactions reported.
No direct food interactions. Avoid eating on the treated side to prevent dislodgement of the fiber. Maintain soft diet to minimize trauma. Avoid alcohol-based mouthwashes.
OXERVATE contains cenegermin, a recombinant human nerve growth factor. No adequate and well-controlled studies in pregnant women. Animal reproductive studies have not been conducted. Risk cannot be ruled out; use only if potential benefit justifies potential risk to fetus. First trimester: unknown risk; second and third trimesters: unknown risk.
FDA Pregnancy Category C. No adequate studies in pregnant women. In animal studies, tetracycline hydrochloride (active component) caused fetal toxicity (skeletal malformations, reduced fetal weight) at doses 1-2 times the human dose. First trimester: potential for teratogenicity (neural tube defects, cardiovascular anomalies). Second and third trimesters: risk of permanent tooth discoloration (yellow-gray-brown) and enamel hypoplasia in the fetus; also potential for inhibition of fetal bone growth and maternal hepatotoxicity. Use only if potential benefit outweighs risk.
No data on presence in human milk, effects on breastfed infant, or milk production. Caution advised; M/P ratio unknown.
Tetracycline is excreted in human milk (M/P ratio approximately 0.6-1.5). Due to potential for serious adverse reactions (tooth discoloration, bone growth inhibition, photosensitivity) in nursing infants, a decision should be made to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. Avoid prolonged use during breastfeeding.
No pharmacokinetic studies in pregnancy; dose adjustments not established. Use standard dosing with caution.
No specific dose adjustments for ACTISITE (tetracycline periodontal fiber). Systemic absorption minimal (peak serum concentrations <0.1 mcg/m L). Pregnancy may alter pharmacokinetics of tetracycline (increased volume of distribution, decreased protein binding), but due to local administration, systemic effects are negligible. No dosage adjustment required for the fiber formulation; however, avoid systemic tetracycline use during pregnancy when possible.
OXERVATE (cenegermin-bkbj) is a recombinant human nerve growth factor for neurotrophic keratitis. Administer as one drop in the affected eye(s) six times daily at 2-hour intervals for 8 weeks. Refrigerate at 2-8°C; do not freeze. Protect from light. Discard unused drops after 1 week of first opening. Monitor for corneal epithelial defect closure. Use with caution in patients with active ocular infections or inflammation.
ACTISITE (tetracycline hydrochloride) periodontal fiber is a controlled-release local antibiotic for adjunctive treatment of chronic periodontitis. Insert fiber into periodontal pocket to deliver drug over 10 days. Ensure pocket depth is ≥5mm. Do not use with metallic or synthetic fibers. Fiber must be secured with cyanoacrylate adhesive. Monitor for foreign body sensation, pain, or infection. Removal at 10 days is mandatory to avoid excessive tissue reaction. Not for acute abscesses.
Wash hands before each use.,Instill one drop in the affected eye(s) every 2 hours, 6 times daily.,Refrigerate the medication at all times; do not freeze.,Use within 1 week after opening the vial.,Avoid touching the dropper tip to any surface.,Do not use contact lenses during treatment.,Report any eye pain, redness, or vision changes immediately.,Complete the full 8-week course even if symptoms improve.
Do not brush or floss the treated area while the fiber is in place.,Avoid chewing hard or sticky foods on the treated side.,You may feel a mild foreign body sensation; report severe pain or swelling.,The fiber must be removed after 10 days; do not leave it longer.,Complete the full course of prescribed oral hygiene and antibiotics if given.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about OXERVATE vs ACTISITE, answered by our medical review team.
OXERVATE is a Growth Factor (Ophthalmic) that works by OXERVATE (becaplermin) is a recombinant human platelet-derived growth factor (rh PDGF-BB) that promotes wound healing by stimulating chemotaxis and mitogenesis of fibroblasts, smooth muscle cells, and other cells involved in tissue repair.. ACTISITE is a Tetracycline Antibiotic that works by Tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-t RNA from binding to the A site.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between OXERVATE and ACTISITE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of OXERVATE is: 1 drop in the affected eye(s) twice daily, approximately 6 hours apart.. The standard adult dose of ACTISITE is: Topical application of tetracycline hydrochloride 10 mg/g periodontal fiber. Inserted into periodontal pocket and left in place for 10 days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between OXERVATE and ACTISITE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. OXERVATE is classified as Category C. OXERVATE contains cenegermin, a recombinant human nerve growth factor. No adequate and well-controlled studies in pregnant women. Animal reproductive studies have not been conducte. ACTISITE is classified as Category C. FDA Pregnancy Category C. No adequate studies in pregnant women. In animal studies, tetracycline hydrochloride (active component) caused fetal toxicity (skeletal malformations, red. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.